Upgrade to SI Premium - Free Trial

BofA maintains Underperform on Esperion Therapeutics (ESPR) despite favorable new AHA/ACC guidelines

March 16, 2026 5:40 PM
BofA Securities analyst Jason Zemanski reiterated an Underperform rating and $1.78 price target on Esperion Therapeutics (NASDAQ: ESPR)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments